The global preterm birth control market is expected to reach US$ 1,809.0 Mn in 2025 from US$ 1,190.5 in 2017. The market is estimated to grow with a CAGR of 4.9% from 2018-2025.
North America is the largest geographic market and it is expected to be the largest revenue generator during the forecast period, whereas the market is expected to witness growth at a significant rate in Asia Pacific (APAC) region during the forecast period. The Asia Pacific per-term birth control market is expected to grow with CAGR of 5.1% to US$ 325.6 Mn in 2025 from US$ 222.4 Mn in 2017.
- Cooper Surgical
- Medgyn Products
- Integra Life sciences Corporation
- Panpac Medical Corp.
- Dr. Arabin GMBH & Co. KG
- Amag Pharmaceuticals
- Ben Way Enterprises Sdn Bhd
- Personal Medical Corp.
- Bioteque America Inc.
- Bliss Gvs Pharma Ltd.
Request for Sample PDF Copy at: https://www.theinsightpartners.com/sample/TIPMD00002026/
Increasing Number of Preterm Births
There has been a gradual increase in the number of preterm births from last few years. As per the World Health Organization (WHO), premature birth is a leading cause of death among the child below 5 years of age. It may be due to early induction of labor or caesarean birth. Multiple pregnancies, infections and chronic conditions such as diabetes and high blood pressure are others common causes of preterm births. As per the Centers for Disease Control and Prevention (CDC), reduction in preterm birth was observed from 2007-2014. In 2015, low birth weight and preterm birth accounted for about 17% of infant deaths. However, the number increased during 2016, with racial and ethnic differences. In the US, 1 of every 10 infants born was a preterm birth.
A number of government and non-government organizations are engaged increasing awareness about preterm birth in various countries across the globe. Organizations such as CDC has implemented strategies to reduce preterm births. These strategies includes provision of healthcare services before and between pregnancies; determining population at the risk of preterm delivery and provide immediate treatment, discouraging deliveries before 39 weeks without a medical need; and preventing unintended pregnancies by waiting for at least 18 months between pregnancies.
The pre-term birth control market by treatment method is segmented into pharmaceutical treatment and devices. The pharmaceutical treatment segment is poised to grow with a largest market share of 55.6% in 2017. The market for pharmaceutical treatment is anticipated to surge during the forecast period from 2017 to 2025, at a significant rate.
Collaborations/ acquisitions were observed as the most adopted strategy in global pre-term birth control industry. Few of the product launches and agreements made by the players in the market are listed below;
2018: CooperSurgical had acquired the assets of The LifeGlobal Group and its affiliates. The LifeGlobal Group is a leading global provider of in-vitro fertilization devices.
PRE-TERM BIRTH CONTROL – MARKET SEGMENTATION
By Treatment method
- Cervical Cerclage
- Vaginal Pessaries
- Pharmaceutical treatment
- North America
- Asia Pacific
- Middle East & Africa
- Saudi Arabia
- South Africa
- South & Central America
Buy Complete Report at: https://www.theinsightpartners.com/buy/TIPMD00002026/
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.